Fact CheckerSign in

NCT07675122Recruiting

Duodenal-jejunal Bypass Sleeve (DJBS) for Obesity and Metabolic Syndrome

Endoscopic Duodenal-jejunal Bypass Sleeve for Treatment of Obesity and Metabolic Syndrome - a Multicenter Pilot Study

Source: ClinicalTrials.gov · Last updated 15 Sept 2026

Brief summary (registry, in English)

This study is designed to evaluate the efficacy, safety, and mechanisms of duodenal-jejunal bypass sleeve in patients with obesity

Status (registry)
Recruiting
Study type
Interventional
Enrollment
20 (estimated)
First submitted
20 Jun 2026
Start date
1 Sept 2026
Primary completion date
31 Jul 2028
Lead sponsor
Chinese University of Hong Kong
Diseases
Obesity
NCT number
NCT07675122

What you commit to

  • Study type: Interventional
  • Planned participants: 20
  • From 1 Sept 2026 to the primary completion date, 31 Jul 2028
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patients who are currently taking weight loss drugs such as orlistat
  • Those who have taken antiplatelet drugs or anticoagulant drugs such as aspirin in the past month
  • Duodenal bulb ulcer, gastric ulcer or previous and existing pancreatitis

Other illness

  • Gastrointestinal malformations, such as patients with gastrointestinal atresia or other patients who will cause gastrointestinal implantation failure
  • Those with a history of cholecystitis and liver abscess
  • There is a known infection, and the type of disease and the severity of the infection are not suitable for use by clinicians
  • Drug or alcohol abuse addiction or suffering from uncontrollable mental illness
  • Coronary heart disease, angina, cardiac function grade III or above, or pulmonary dysfunction
  • Patients with potential bleeding or telangiectasia in the stomach, esophagus, small intestine and other parts
  • Have a history of systemic lupus erythematosus, scleroderma
  • Those who are allergic to nickel-titanium

Lab values

  • Severe liver and kidney dysfunction, AST /ALT \> 2.5 times, total bilirubin \> 35 μmol/L, blood creatinine concentration greater than 180 μmol/L

Other

  • Patients who have lost more than 5 kg of weight in the past three months
  • Patients who have used glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the past three months
  • iron deficiency or iron deficiency anemia
  • coagulation dysfunction;
  • Patients with ASA IV \& V
  • Patients who have undergone ERCP before
  • Those who have contraindications to endoscopy (judged by clinicians)
  • Pregnant women or those who are preparing to become pregnant
  • Any other situation that the clinician deems unsuitable for participation in this product

Who the study is looking for

  • Body mass index (BMI) ≥27.5kg/m2; or BMI ≥25 kg/m2 with metabolic syndrome

Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Chinese University of Hong Kong
Coordinator of this site? Confirm its status
ShatinHong Kong SAR ChinaRecruiting
CUHK Medical Centre
Coordinator of this site? Confirm its status
ShatinHong Kong SAR ChinaNot yet recruiting

This page is information, not medical advice. Discuss any trial with your doctor.